GD2-CAR-iNKT cells persistence and anti-tumor activity can be further increased wit CAR constructs co-expressing human IL-15 (133), while increasing the expression of CD1d on B-lymphoma or leukemia cells with epigenetic drugs substantially enhanced their targeting by CD19-CAR-iNKT cells, resulting in markedly improved cancer control in mouse xenograft models (131). This evidence concerns the gene CD19 and leukemia.